Clinical Trial Detail

NCT ID NCT03052569
Title Expanded Access to RXDX-105 for Cancers With RET Alterations
Recruitment No longer available
Gender both
Phase Expanded access
Variant Requirements Yes
Sponsors Ignyta, Inc.
Indications

Advanced Solid Tumor

Therapies

RXDX-105

Age Groups: adult child senior

Additional content available in CKB BOOST